Search Results for "Disadvantages Is Bare Metal Stents"
Original Source: Drug-Eluting Stents vs. Bare Metal Stents In Saphenous Vein Graft Angioplasty
Patients who have undergone coronary bypass surgery have had a vein removed from the leg and implanted in the chest to "bypass" blockages in the coronary arteries. These veins are called saphenous vein grafts or SVGs. SVGs often develop blockages that can cause chest pain and heart attacks. SVG blockages can be opened by using small balloons and stents (metal coils that keep the artery open). Two types of stents are currently used: bare metal stents (BMS) and drug-eluting sten...
Matching Channels
Devices - medical, biotech, pharma
A medical device is a product which is used for medical purposes in patients, in diagnosis, therapy or surgery. Medical devices act by physical, mechanical, thermal, physico-chemical or chemic...
With annual sales reaching $15 billion in 2010, Medtronic is the 4th largest medical devices company in the world (based on annual sales). The device portfolio of Medtronic is broad; covering card...
Matching News
Vanishing-Polymer DES Beat Bare-Metal Stents in STEMI
A newer-generation biolimus-eluting stent with a biodegradable polymer showed better efficacy than a bare-metal stent in STEMI patients and a hint at superior safety in the COMFORTABLE AMI study, whic...
Rarely tested in patients over the age of 80, a study found that drug-eluting stents exhibited some benefits over bare-metal stents, though both types of stents demonstrated a clinical benefit. Result...
Drug-Eluting Stents Offer Some Benefits Over Bare-Metal Stents In Patients Over 80
Results of the XIMA trial presented at TCT 2012 Rarely tested in patients over the age of 80, a study found that drug-eluting stents exhibited some benefits over bare-metal stents, though both types...
ContextThe efficacy and safety of drug-eluting stents compared with bare-metal stents remains controversial in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percu...
Objectives To evaluate the efficacy and safety of currently used drug eluting stents compared with each other and compared with bare metal stents in patients with diabetes.Design Mixed treatment......
[Comment] EXAMINATION of new drug-eluting stents—top of the class!
The introduction of drug-eluting stents was heralded as a key development in cardiovascular medicine because of the large relative and absolute reductions in repeat coronary procedures compared with b...
Colchicine Prevents Bare-Metal Stent Restenosis in Diabetics
Colchicine reduces neointimal hyperplasia and in-stent restenosis in diabetics who receive bare-metal coronary stents, Greek researchers say. Reuters Health Information
Everolimus-Eluting Stents Perform Best in Diabetics
A new meta-analysis compares various drug-eluting stents and bare-metal stents to see which one yields the best outcomes in patients with diabetes. Heartwire
Matching PubMed Articles
PURPOSE: To compare postintervention patency rates after deployment of bare metal versus covered stents across the venous anastomosis of prosthetic arteriovenous (AV) grafts. METHODS: Review of our pr...
The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents.
Human coronary bare-metal stents (BMS) and drug-eluting stents (DES) from autopsy cases with implant duration >30 days were examined for the presence of neointimal atherosclerotic disease.
The study investigated the long-term clinical impact of sirolimus-eluting stents (SES) in comparison with bare-metal stents (BMS) in treatment of focal infrapopliteal lesions.
Drug-eluting stents versus bare-metal stents for treatment of bare-metal in-stent restenosis.
Objectives: We compared the long-term outcomes of drug-eluting stents (DES) versus bare-metal stents (BMS) for treatment of bare-metal in-stent restenosis (ISR). Background: There are no randomized tr...
To assess whether there are differences in the rate of restenosis between bare metal stents (BMS) and drug eluting stents (DES) implanted for the treatment of cardiac allograft vasculopathy (CAV).
